Cannabidiol for liver cirrhosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Jul 2021: Trial started, NCT05044819
  2. 16 Sep 2021: Trial registered, NCT05044819

The trials

NCT05044819: Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

State
Under way
Phase
Phase 4
People
154 taking part
Started
7 Jul 2021
Primary completion
1 Aug 2027
Arms
Cannabidiol
Results
None posted
  1. 7 Jul 2021: Trial started
  2. 16 Sep 2021: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.